Gynaecological cancer: Therapeutic HPV vaccine holds promise

Nature Reviews Clinical Oncology

Volumn 12, Issue 12, 2015, Pages 686-

  Killock, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; PLACEBO; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VGX 3100; WART VIRUS VACCINE;

ANTIBODY RESPONSE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INTENTION TO TREAT ANALYSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRAL CLEARANCE; VIRUS STRAIN; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 84948386177     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.180     Document Type: Note

References (1)

1. Trimble, C. L. et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet doi:10.1016/S0140-6736(15)00239-1